BUTORPHANOL TARTRAT

The contract is for the procurement of Butorphanol Tartrate Injection, a veterinary pharmaceutical used for pain relief associated with colic in adult horses and yearlings. The product is supplied in 50 ml vials, each containing 10 mg/ml of the active ingredient, and is classified as a DEA Schedule IV controlled substance. The item must be stored at controlled room temperature between 20-25°C (68-77°F) and secured according to its controlled substance status. Packaging and marking are required to comply with the latest Medical Marking Standard No. 1 and Defense Logistics Agency packaging requirements, ensuring that the product meets strict technical and quality standards set forth in the Defense Logistics Agency master list. The contract specifies a unit of issue as a single 50 ml vial, with a non-extendable 24-month shelf life. Delivery is expected within 89 days, with inspection and acceptance occurring at the destination. The purchase is managed by the Department of Defense Medical Supply Chain Pharm FSA, with multiple manufacturers and suppliers identified for source legitimacy. Removal of government identification is required from non-accepted supplies, and the procurement follows federal regulatory guidelines, including FDA oversight. The solicitation aims at ensuring reliable supply and quality assurance for this veterinary drug under controlled handling conditions.